Oral formulations of cedazuridine and decitabine for patients with MDS
Hypomethylating agents (HMAs), such as azacitidine and decitabine, are the main treatment options for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
How should molecular profiling be used to guide MDS therapy?
During the Acute Leukemia Forum (ALF) 2021, the MDS Hub spoke to Rafael Bejar, UC San Diego, San Diego, US. We asked, How should molecular profiling be used to guide MDS therapy?
"The MDS Hub allows you to access the most relevant updates in myelodysplastic syndromes and related disorders. We aim to deliver valuable and up-to-date information and expert opinions to all physicians practicing hemato-oncology."